Midazolam

Trade name

B.Braun Midazolam, Hypnovel, Midazolam (Accord), Midazolam (Apotex), Midazolam (Pfizer), Midazolam (Viatris), Midazolam (Baxter)

Strength

1 mg/mL (volume: 5 mL, 50 mL, 100 mL)

5 mg/mL (volume: 1 mL, 3 mL, 10 mL)

IV administration

Use undiluted or dilute to a convenient volume and give over at least 2 – 5 minutes or further dilute to 0.5 mg/mL and give as a continuous infusion.

Preterm neonates: infuse loading doses over 60 minutes.

Other routes of administration

IM: Suitable. Give undiluted using 1 mg/mL solution by deep injection into a large muscle.

SC: Suitable. May be given as an intermittent or continuous SC infusion in palliative care settings.

Compatible IV fluids

Midazolam 1 mg/mL or weaker:

Glucose 5%

Glucose 5% and sodium chloride 0.9%

Midazolam 0.5 mg/mL or weaker:

Glucose 10%

Midazolam 3 mg/mL or weaker:

Sodium chloride 0.9%

Y-site only:

Potassium chloride 20 mmol/L

Y-site only and Midazolam 0.5 mg/mL or weaker:

Hartmann’s

Y-site only and Midazolam 2.5 mg/mL or weaker:

Ringer's

Y-site only and midazolam 1 mg/mL or weaker:

Plasma-Lyte 148

Additional information

Extravasation risk.

Use only when facilities for cardiac monitoring and cardio-respiratory resuscitation exist.

Rapid administration may cause severe hypotension, respiratory depression and seizure activity. Paradoxical reactions, including hyperactivity or aggressive behaviour may occur.

Concomitant use of other CNS depressants (e.g. opioids), IM olanzapine, increases the risk of respiratory depression, sedation, coma, and death.

Taper the infusion slowly when discontinuing treatment; abrupt discontinuation may cause signs and symptoms of withdrawal.

Solution should be clear and colourless to light yellow.

Protect from light during storage.